Table 3.
Test Group | Dose/24 hr | Compound Measured |
Plasma Concentration (ng/mL )± S.E.M. N=6-12 |
Estimated Human Therapeutic Plasma Range (ng/mL)* |
||
---|---|---|---|---|---|---|
15 Days | 90 days | 180 days | ||||
haloperidol | 2.0 mg/kg | haloperidol | 6.4 ± 0.9 | 11.5 ± 2.4 | 12.4 ± 2.8 | 4.0-18.0 |
risperidone | 2.5 mg/kg | risperidone | 4.7 ± 1.3 | 7.4 ± 2.8 | 4.3 ± 1.6 | |
9-OH risperidone | 22.5 ± 3.5 | 30.2 ± 8.8 | 22.8 ± 7.4 | |||
risperidone + 9-OH risperidone |
27.2 ± 4.6 | 37.5 ± 11.5 | 27.1 ± 8.9 | 20.0-60.0 |
Estimated human therapeutic plasma ranges listed are based on Baldessarini et al., 1988; Markowitz and Patrick, 1996; Coryell et al., 1998; Balant-Gorgia et al., 1999.